Big results for bladder cancer drug
A new type of drug has been shown to reduce bladder cancer deaths by up to 30 per cent.
Researchers in the UK are testing a drug that helps target chemotherapy directly to cancer cells.
In studies so far, it has been found to reduce deaths by 30 per cent in patients with urothelial cancer - the most common form of bladder cancer.
The latest results come from a Phase III clinical trial in 608 patients from 19 countries. This type of trial tests a treatment in a large group of patients to determine how effective it is.
The new drugs are known as ‘antibody-drug conjugates’ (ADC), and consist of an antibody attached to a chemotherapy-like drug.
The antibody targets cancer cells, carrying the chemotherapy-like drug with it, so it only affects cancer cells and ignores healthy cells.
The drug is called enfortumab vedotin.